

Report of transactions
No. 01/2014

Report of transactions in Zealand's shares and related securities by executives and their related parties

Copenhagen, 11 April 2014 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S (Zealand) shall announce transactions in the company's shares and related securities by executives and persons/companies closely related to them.

In this regard, Zealand announces the following transaction:

Name:	Jørgen Lindegaard
Reason:	Vice Chairman of the Board of Directors
Issuer:	Zealand Pharma A/S
Type	Shares
ISIN code:	DK0060257814
Transaction:	Purchase
Trading date:	10 April 2014
Market:	NASDAQ OMX København A/S
Amount:	2,000
Price:	DKK 65.50
Market value:	DKK 131,000.00

Following the above transaction, Jørgen Lindegaard owns a total of 16,285 shares in Zealand.

For further information, please contact:

David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300

Hanne Leth Hillman, Vice President, Head of Investor Relations & Corporate Communications - Tel: +45 50 60 36 89, email: hlh@zealandpharma.com



About Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) ("Zealand") is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company's focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia®) is approved in several countries globally, including Europe and Japan. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA Cardiovascular outcome study. In February 2014, Sanofi started the pivotal Phase 3 clinical program for the Lantus®/Lyxumia® combination product (LixiLan).

Zealand has a partnering strategy for the development and commercialization of its products and, in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.

For further information: zealandpharma.com

Follow us on Twitter @ZealandPharma